Perspective Therapeutics CEO buys 47,000 shares

Available on EDGAR 11/12/2026 - 08:30 AM EST Accepted by SEC EDGAR 11/12/2026 - 08:30 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. Chief Executive Officer Johan M. Spoor purchased 47,000 common shares on November 11, 2026, at a weighted average price of $0.8073 per share; the multiple transactions ranged from $0.8007 to $0.8157 per share. His direct holdings afterward were 106,383 shares. Reported indirect holdings included 5,400 shares in his IRA, 12,600 shares in his spouse’s IRA, 1,000 shares held by his spouse, and 4,650 shares held by each of two children. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 47,000 shares

Net Buy 1 txn

Insider Spoor Johan M.

Role Chief Executive Officer

Bought 47,000 shs ($38K)

Increase in Position 79.1%

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	47,000	$0.8073	$38K
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--
Holding	Common stock	--	--	--

Holdings After Transaction: Common Stock — 106,383 shares (Direct); Common Stock — 5,400 shares (Indirect, By IRA of Reporting Person); Common Stock — 12,600 shares (Indirect, By IRA of Spouse); Common Stock — 1,000 shares (Indirect, By Spouse); Common Stock — 4,650 shares (Indirect, By Child #1); Common stock — 4,650 shares (Indirect, By Child #2)

Holdings Before and After: Common Stock, 59,383 to 106,383 shares (Direct)

Footnotes (1)

1. F1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8007 to $0.8157, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

Key Figures

Common shares purchased: 47,000 shares Weighted average purchase price: $0.8073 per share Purchase price range: $0.8007 to $0.8157 per share +5 more

8 metrics

Common shares purchased 47,000 shares November 11, 2026

Weighted average purchase price $0.8073 per share Multiple transactions on November 11, 2026

Purchase price range $0.8007 to $0.8157 per share Multiple transactions

Direct holdings after purchase 106,383 shares November 11, 2026

Shares held in Johan M. Spoor’s IRA 5,400 shares Reported November 11, 2026

Shares held in spouse’s IRA 12,600 shares Reported November 11, 2026

Shares held by spouse 1,000 shares Reported November 11, 2026

Shares held by each of two children 4,650 shares Reported November 11, 2026

Key Terms

weighted average price, IRA

2 terms

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

IRA financial

"By IRA of Reporting Person"

An individual retirement account (IRA) is a savings account designed to help people put aside money for their retirement, often with tax advantages that encourage long-term savings. It matters to investors because it can grow over time, providing financial security later in life, and offers benefits that can reduce current taxes or allow investments to compound more effectively.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CATX shares did CEO Johan M. Spoor buy, and at what price?

Johan M. Spoor purchased 47,000 common shares on November 11, 2026, at a weighted average price of $0.8073 per share. The purchases were made in multiple transactions at prices ranging from $0.8007 to $0.8157 per share, and no Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spoor Johan M.

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WASHINGTON 98121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2026		P		47,000	A	$0.8073(1)	106,383	D
Common Stock								5,400	I	By IRA of Reporting Person
Common Stock								12,600	I	By IRA of Spouse
Common Stock								1,000	I	By Spouse
Common Stock								4,650	I	By Child #1
Common stock								4,650	I	By Child #2

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8007 to $0.8157, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

	/s/ Johan (Thijs) Spoor by Chris Nenno, as Attorney-in-Fact	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)